Tumor-Associated GD1a Ganglioside Antigen Production Service at CD BioGlyco

CD BioGlyco utilizes the advanced Glyco™ Vaccine Development Platform to offer efficient Carbohydrate-based Vaccine Development service to our clients. We assist clients in the development of promising Tumor-Associated Carbohydrate Vaccine Development by providing the professional tumor-associated GD1a ganglioside antigen production service. We offer a wide range of services, including but not limited to the following:

• We use specific enzymes to catalyze the reaction GD1a ganglioside, including acidases, glucosyltransferases, glycosidases, and glycosyltransferases. These enzymes catalyze specific reaction steps to synthesize GD1a gangliosides under appropriate conditions.
• We normally use monosaccharides or oligosaccharides with specific glycan structures as starting materials for a series of glycan modification reactions and linkage reactions to synthesize GD1a gangliosides. After completing the glycan modification, the lipid group is attached to the glycan structure and finally purified and structurally characterized.
• We first select suitable microbial strains, inoculate them into the specific culture medium, and activate the metabolic pathways related to GD1a synthesis in the microbial strains by adjusting the cultivation conditions, adding specific inducing substances, or utilizing genetic engineering techniques. After completing the fermentation, the microorganisms are separated by centrifugation and filtration, and then the purification technique is used to purify GD1a.

Fig.1 Classification of GD1a ganglioside antigen production methods. (CD BioGlyco)

The GD1a ganglioside antigen shows promise as a potential vaccine candidate, capable of activating the immune system to generate antibodies and targeted cellular immune responses against this antigen. On this basis, we also provide anti-tumor vaccine development services based on GD1a ganglioside antigen to help you accelerate the process of carbohydrate vaccine development.

Applications

• The early identification of tumors becomes feasible through the detection of GD1a ganglioside antigen associated with tumors. Therefore, the utilization of the synthetic antigen allows for the optimization of the detection method and enhances its sensitivity, resulting in improved accuracy and reliability of the detection results.
• The GD1a ganglioside antigen, which is associated with tumors, can serve as a valuable target for the development of drugs that specifically attack cancer cells expressing it.

Publication

Frequently Asked Questions

• What is the structure of the tumor-associated GD1a ganglioside antigen?

It consists of a sphingolipid moiety with polysaccharide chains. The sphingolipid moiety consists mainly of docosahexaenoic acid bound to neuraminic acid (Neu5Ac). The polysaccharide chain is composed of monosaccharides such as galactose, Neu5Ac, and N-acetylgalactosamine.

CD BioGlyco is actively collaborating with the continuous development and progress of novel antigen production methods to enhance our technology for delivering an improved tumor-associated GD1a ganglioside antigen production service to our clients. If you are interested in our service, please feel free to contact us.

References

1. Blixt, O.; et al. Chemoenzymatic synthesis of 2-azidoethyl-ganglio-oligosaccharides GD3, GT3, GM2, GD2, GT2, GM1, and GD1a. Carbohydrate research. 2005, 340(12): 1963-1972.
2. Cutillo, G.; et al. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cellular & molecular immunology. 2020, 17(4): 313-322.